- Home
- Equipment
- usa new york
- disease patient
Show results for
Refine by
Disease Patient Equipment Supplied In Usa New York
10 equipment items found
by:VisualDx based inRochester, NEW YORK (USA)
VisualDx is the award-winning diagnostic clinical decision support system used by more than 2,300 hospitals, clinics, and medical schools around the world. Get the answers you need when you need ...
Manufactured by:UroGen Pharma, Inc. based inPrinceton, NEW YORK (USA)
UroGen is developing UGN-102 (mitomycin) for intravesical solution as a primary nonsurgical alternative to repetitive TURBT. UGN-102 is an investigational formulation that utilizes our innovative technology, RTGel™ reverse-thermal hydrogel, for the treatment of low-grade NMIBC. Instilled via standard catheters, UGN-102 is designed to dwell for a period of several hours before being excreted ...
Manufactured by:Vitalis, LLC based inNew York, NEW YORK (USA)
ER (extended-release) niacin currently has six FDA approved indications and has been prescribed to millions of patients in the U.S. alone (Jackevicius et al.). However, a well-known side effect of treating with ER niacin is Niacin Flush (Mills et al.). The Niacin Flush is a historical term for the medical syndrome of the “skin on fire” experience of these patients. Niacin Flush can be ...
Manufactured by:Mesoblast Ltd. based inMelbourne, AUSTRALIA
MPC-25-IC is Mesoblast’s Phase 2 product candidate for the treatment of acute myocardial infarction. This is the first clinical study to evaluate an allogeneic cellular therapy delivered by intracoronary infusion in patients who have suffered an acute myocardial ...
Manufactured by:IN8Bio Inc. based inNew York, NEW YORK (USA)
Our DeltEx platform has enabled a deep pipeline of preclinical and clinical product candidates, which are designed to effectively target and potentially eradicate disease, to improve patient ...
Manufactured by:Mesoblast Ltd. based inMelbourne, AUSTRALIA
MPC-25-Osteo for spinal fusion is a proprietary Phase 3-ready product candidate. All doses of MPC-25-Osteo for the treatment of spinal fusion consist of 25 million MPCs delivered on a collagen ceramic carrier material into the disc space with stabilizing ...
Manufactured by:Mesoblast Ltd. based inMelbourne, AUSTRALIA
Revascor is a Phase 3 product candidate being developed as a treatment for both advanced and end-stage chronic heart failure ...
Manufactured by:Population Bio, Inc. a Precision Medicine Company based inMelville, NEW YORK (USA)
Population Bio’s patented CNV Beacon® platform is a rapid genetic discovery method that focuses first on identifying disease-relevant copy number variants (CNVs). Once a gene or genomic region is discovered via a CNV, other types of genetic variants – such as single nucleotide variants (SNVs) – can be efficiently revealed to determine the full spectrum of variants that cause ...
Manufactured by:Mesoblast Ltd. based inMelbourne, AUSTRALIA
MPC-06-ID is a Phase 3 product candidate for the treatment of chronic low back pain caused by disc degeneration (CLBP). It is being developed for patients who have exhausted conservative treatment options, may have failed epidural steroid injections and have no further treatment option other than invasive and costly surgical ...
Manufactured by:Mesoblast Ltd. based inMelbourne, AUSTRALIA
MPC-300-IV is being developed for the treatment of diabetic complications, including diabetic kidney disease known as diabetic ...